annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION
Gynecologic Cancer
Display Time: 2:00 PM - 6:00 PM
Display Location: E450a
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E Arie Crown Theater
CME credit: 1
Track(s): Gynecologic Cancer
Claire F. Verschraegen, MD—Co-Chair
University of New Mexico
Seiko Diane Yamada, MD—Co-Chair
The University of Chicago
Discussion
5:00 PM Carol Aghajanian, MD (Abstracts #5009–5015)
Memorial Sloan-Kettering Cancer Center
Old Wines in New Bottles
Discussion
5:15 PM Michael J. Birrer, MD, PhD (Abstracts #5016–5023)
Harvard Medical School, Massachusetts General Hospital
Biomarkers in Ovarian Cancer: Ready for Prime Time?
Discussion
5:30 PM Angeles Alvarez Secord, MD (Abstracts #5024–5029)
Duke University Medical Center
What’s New in Endometrial Cancer?
Discussion
5:45 PM Martin Stockler, MBBS, FRACP, MHS (Abstracts #5030–LBA5033)
NHMRC Clinical Trials Centre, University of Sydney
Mining Phase III Studies: Gold or Quicksilver?
Brd. 1 A phase II study of bevacizumab with nab-paclitaxel in patients with
recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal
carcinoma. (Abstract #5009)
T. D. Tillmanns, M. P. Lowe, L. S. Schwartzberg, M. S. Walker, E. J. Stepanski
Brd. 2 A phase II evaluation of nab-paclitaxel in the treatment of recurrent or
persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal
cancer: A Gynecologic Oncology Group (GOG) study. (Abstract #5010)
R. L. Coleman, W. Brady, D. S. McMeekin, P. G. Rose, J. T. Soper, S. S. Lentz,
J. S. Hoffman, M. S. Shahin
Brd. 3 A phase II nonrandomized study of nab-paclitaxel plus carboplatin in
patients with recurrent platinum-sensitive ovarian or primary peritoneal
cancer. (Abstract #5011)
B. B. Benigno, M. O. Burrell, P. Daugherty, P. Hernandez
Brd. 4 Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS)
patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin
(Tr) plus pegylated liposomal doxorubicin (Tr�PLD) versus PLD alone:
Results from a PPS cohort of a phase III study. (Abstract #5012)
A. Poveda, S. Tjulandin, B. Kong, M. Roy, S. Chan, E. Filipczyk-Cisarz,
H. Hagberg, C. Lebedinsky, T. V. Parekh, B. J. Monk
Brd. 5 PRECEDENT: A randomized phase II trial comparing EC145 and pegylated
liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects
with platinum-resistant ovarian cancer. (Abstract #LBA5012b)
R. W. Naumann, J. T. Symanowski, S. A. Ghamande, N. Y. Gabrail, L. Gilbert,
M. G. Teneriello, G. Sutton, C. Lovejoy, R. A. Messmann
250